GCL
TERN

Glazer Capital LLC’s Terns Pharmaceuticals TERN Stock Holding History

Glazer Capital LLC’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121M Buy
+2,295,498
New +$94.3M 2.57% 10

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Glazer Capital LLC's TERN Position: Q1 2026 in Review

Glazer Capital LLC opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 2,295,498 shares worth $121M. The stake represents 2.57% of the portfolio and ranks #10 among its holdings.

317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Glazer Capital LLC held 2,295,498 shares of Terns Pharmaceuticals worth $121M as of Q1 2026.
  • Terns Pharmaceuticals was a new Glazer Capital LLC position in Q1 2026.
  • Terns Pharmaceuticals made up 2.57% of Glazer Capital LLC's portfolio in Q1 2026, its #10 holding.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.